

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

KHOS/NP

RRID:CVCL_2546

Type: Cell Line

Proper Citation

RRID:CVCL_2546

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2546

Proper Citation: RRID:CVCL_2546

Description: Cell line KHOS/NP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:2233717](#), [PMID:2978869](#), [PMID:20215515](#), [PMID:26351324](#), [PMID:28196595](#)

Comments: Characteristics: Tumorigenic., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KHOS/NP

Synonyms: KHOS-NP, KHOS NP, KHOSNP, R-970-5, KHOS

Cross References: BTO:BTO_0003922, CLO:CLO_0007096, CLO:CLO_0007097, CLO:CLO_0008725, CLDB:cl3030, CLDB:cl3031, ATCC:CRL-1544, ATCC:CRL-7723, cancercellines:CVCL_2546, ChEMBL-Cells:ChEMBL3308001, ChEMBL-Targets:ChEMBL612598, CLS:300235, Cosmic:1044083, Cosmic:1074393, ECACC:84102903, GEO:GSM186428, GEO:GSM186429, GEO:GSM827385, GEO:GSM1676341, GEO:GSM1701672, IZSLER:BS TCL 80, LINCS_LDP:LCL-1425, Progenetix:CVCL_2546, PubChem_Cell_line:CVCL_2546, Wikidata:Q54899911

ID: CVCL_2546

Hierarchy: cvcl_0439

Record Creation Time: 20220427T220702+0000

Record Last Update: 20260829T234413+0000

Ratings and Alerts

No rating or validation information has been found for KHOS/NP.

Warning: Discontinued: ATCC; CRL-7723

Characteristics: Tumorigenic., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xu J, et al. (2023) Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma. *Frontiers in oncology*, 13, 1192472.

Takemoto A, et al. (2022) Targeting Podoplanin for the Treatment of Osteosarcoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(12), 2633.

Morice S, et al. (2020) The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth. *Cancers*, 12(12).